COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00374699
Recruitment Status : Completed
First Posted : September 11, 2006
Last Update Posted : October 14, 2009
Janssen Medical Affairs
Information provided by:
Samsung Medical Center

Brief Summary:

Peripheral T-cell lymphomas (PTCLs) are neoplasias from post-thymic T-cells at different stages of differentiation and are a heterogeneous group of malignancies which present with different morphological patterns, phenotypes, and clinical presentations.

These tumours have a striking epidemiological distribution with a lower incidence in Western countries than in Asia. In Korea, PTCLs including T- or natural killer (NK)-cell lymphomas constitute approximately 25 to 35% of all non-Hodgkin's lymphomas. This incidence is quite similar to that of other Eastern Asian countries, including Japan, Hong Kong, and China.

Recent studies suggest that the T-cell phenotype is an independent significant prognostic factor, with PTCLs having one of the lowest overall survival and failure-free survival rates. Based on the investigator's experience, the overall complete remission rate was 61.2% (95% confidence interval [CI]: 48.5-72.8%) and the 5-year probability of failure-free survival was 33.5%. Median survival of all patients was 45 months (range 0-64+ months) and the 5-year probability of survival was 36.2%. Rassidakis et al. reported that expression of pro-apoptotic proteins BAX and BCL-XS, may explain the poor response of many types of PTCL to standard chemotherapy.

To overcome such poor outcome, the optimal therapy for PTCLs remains to be defined. However, because of the rarity of the disease in Western countries, only a few trials have been reported.

Bortezomib (Velcade) is a modified dipeptidyl boronic acid, and a reversible inhibitor of the chymotrypsin-like activity of the 26S proteosome. Bortezomib may induce tumor cell apoptosis or decreased bcl-2 associated drug resistance. Through phase II studies, single agent bortezomib in patients with relapsed indolent and mantle cell lymphomas showed its activity. And also preliminary data indicate that bortezomib can be safely administered in combination with dose adjusted etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy. Therefore, it can be possible to improve the poor outcome of patients with PTCLs by a combination of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) with bortezomib as a first-line therapy.

Primary Hypothesis: Based on the clinical trials and experimental data, bortezomib can overcome pro-apoptotic proteins BAX and BCL-XS induced drug resistance.

Condition or disease Intervention/treatment Phase
Peripheral T-Cell Lymphomas Non-Hodgkin Lymphoma Drug: Velcade Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 55 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Bortezomib + CHOP in Patients With Advanced Stage Aggressive T Cell or NK/T Cell Lymphomas
Study Start Date : April 2006
Actual Primary Completion Date : September 2009
Actual Study Completion Date : October 2009

Primary Outcome Measures :
  1. To define the dose-limiting toxicity and maximum tolerable dose [ Time Frame: Phase I ]
  2. To evaluate the overall response rate [ Time Frame: Phase II ]

Secondary Outcome Measures :
  1. To evaluate the safety and tolerability of the treatment combination [ Time Frame: Phase I/II ]
  2. To estimate the time to progression and the duration of overall response [ Time Frame: Phase II ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Histologically confirmed PTCLs and NK/T cell lymphomas excluding anaplastic lymphoma kinase (ALK)-positive anaplastic large cell T-cell lymphomas (ALCL)
  • Performance status (ECOG) ≤ 3
  • Age ≤ 65
  • At least one or more unidimensionally measurable lesion(s)

    • ≥ 2 cm by conventional computed tomography (CT)
    • ≥ 1 cm by spiral CT
    • skin lesion (photographs should be taken)
    • measurable lesion by physical examination
  • Laboratory values

    • Creatinine (Cr) < 1.5 mg% or creatinine clearance (Ccr) > 50 ml/min
    • Transaminase < 3 X upper normal value
    • Bilirubin < 2.0 mg/dl
    • Absolute neutrophil count (ANC) > 1,500/ul
    • Platelets > 75,000/ul
  • Informed consent
  • Ann Arbor stage III or IV

Exclusion Criteria:

  • Any other malignancies within the past 5 years except basal cell skin cancer or carcinoma in situ (CIS) of the cervix
  • Serious comorbid diseases
  • Pregnancy or breast feeding

Any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by-case basis prior to enrolling the subject. This must be documented by both the sponsor and the investigator. No subject will be allowed to enroll in this study more than once.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00374699

Layout table for location information
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Samsung Medical Center
Janssen Medical Affairs
Layout table for investigator information
Principal Investigator: Won Seog Kim, MD, PhD Samsung Medical Center
Layout table for additonal information
Responsible Party: CISL (Consortium for Improving Survival of Lymphoma) Identifier: NCT00374699    
Other Study ID Numbers: 2005-07-021
First Posted: September 11, 2006    Key Record Dates
Last Update Posted: October 14, 2009
Last Verified: June 2007
Keywords provided by Samsung Medical Center:
Peripheral T-cell lymphomas(PTCLs)
natural killer (NK)-cell lymphomas
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents